(Q36258557)

English

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

0 references

1 reference

Europe PubMed Central

Systematic review of randomized controlled trials of atypical antipsychotics and selective serotonin reuptake inhibitors for behavioural problems associated with pervasive developmental disorders (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

systematic review

1 reference

based on heuristic

inferred from title

author name string

Dinca O

1

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Paul M

2

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Spencer NJ

3

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

language of work or name

0 references

publication date

1 September 2005

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

19

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

521-532

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Whole blood serotonin in autistic and normal subjects.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Assessment in multisite randomized clinical trials of patients with autistic disorder: the Autism RUPP Network. Research Units on Pediatric Psychopharmacology

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Prevalence of the fragile X anomaly amongst autistic twins and singletons.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

A systematic review of the use of atypical antipsychotics in autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Association of tuberous sclerosis of temporal lobes with autism and atypical autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

The Vineland Adaptive Behavior Scales: supplementary norms for individuals with autism.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone for aggression and self-injurious behavior in adults with mental retardation

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Fluoxetine Treatment of Children and Adults with Autistic Disorder and Mental Retardation

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Medication-induced hypomania in Asperger's disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Amisulpride versus bromocriptine in infantile autism: a controlled crossover comparative study of two drugs with opposite effects on dopaminergic function

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Fluoxetine in autism with depression

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Outcome in autism and autistic-like conditions

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

A crossover study of risperidone in children, adolescents and adults with mental retardation.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone and explosive aggressive autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Pharmacological treatment of mood disturbances, aggression, and self-injury in persons with pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Behavior checklist for identifying severely handicapped individuals with high levels of autistic behavior.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Tardive dyskinesias and antipsychotics: a review

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Autism diagnostic observation schedule: a standardized observation of communicative and social behavior

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Olanzapine versus haloperidol in children with autistic disorder: an open pilot study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone treatment in children and adolescents with autism: short- and long-term safety and effectiveness

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Open-label quetiapine in the treatment of children and adolescents with autistic disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone monotherapy in preschool children with pervasive developmental disorders.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Open trial of risperidone in 24 young children with pervasive developmental disorders.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Serotonergic responsivity in male young adults with autistic disorder. Results of a pilot study

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone in children with autism and serious behavioral problems

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Case series: use of ziprasidone for maladaptive symptoms in youths with autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Effects of tryptophan depletion in drug-free adults with autistic disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Fluvoxamine treatment of coincident autistic disorder and obsessive-compulsive disorder: a case report.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Fluoxetine and autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Use of citalopram in pervasive developmental disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

An open trial of risperidone in young autistic children.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Fluoxetine in children with autism.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Paroxetine in autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone in the treatment of two very young children with autism.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Risperidone for young children with mood disorders and aggressive behavior

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

A retrospective chart review of risperidone use in treatment-resistant children and adolescents with psychiatric disorders

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Paroxetine for self-injurious behavior.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Selective serotonin reuptake inhibitor-related extrapyramidal symptoms in autistic children: a case series

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Recent advances in the pharmacotherapy of autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Pervasive developmental disorders: a 10-year review

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Open-label risperidone treatment of 6 children and adolescents with autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Comorbid association of autism and schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

The serotonin system in autism

1 reference

https://api.crossref.org/works/10.1177%2F0269881105056541

21 January 2018

Identifiers

10.1177/0269881105056541

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36258557&oldid=1622450155"